Grant award to consolidated subsidiary (REPROCELL USA Inc.)
REPROCELL USA Inc. (our wholly owned subsidiary)
Clinical-grade universal donor iPS cells (project name: Generation of hypoimmune iPSC seed stocks for clinical applications)
Total grant ceiling: $398,535 (approximately ¥63 million). Accounting classification: Not disclosed
The impact on our financial results is currently expected to be immaterial.
Related procedures
Maryland Technology Development Corporation（TEDCO）、Maryland Stem Cell Research Fund（MSCRF）
The grant project period runs from June 2026 to May 2027. REPROCELL USA Inc. will produce and commercialize clinical-grade universal donor iPS cells, while our Group will work to strengthen its business base and expand its operations.
Should any matters requiring disclosure arise, we will promptly announce them.
| Item | Details |
|---|---|
| Event name | Grant award to consolidated subsidiary (REPROCELL USA Inc.) |
| Subject Entity | REPROCELL USA Inc. (our wholly owned subsidiary) |
| Target Locations / Products | Clinical-grade universal donor iPS cells (project name: Generation of hypoimmune iPSC seed stocks for clinical applications) |
| Amount of Impact on Business Performance | Total grant ceiling: $398,535 (approximately ¥63 million). Accounting classification: Not disclosed |
| Impact on Earnings Forecast | The impact on our financial results is currently expected to be immaterial. |
| Court or authority | Maryland Technology Development Corporation（TEDCO）、Maryland Stem Cell Research Fund（MSCRF） |
| Outlook | The grant project period runs from June 2026 to May 2027. REPROCELL USA Inc. will produce and commercialize clinical-grade universal donor iPS cells, while our Group will work to strengthen its business base and expand its operations. |
| Planned follow-up disclosure | Should any matters requiring disclosure arise, we will promptly announce them. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.REPROCELL USA Inc. will combine the gene-editing technology “StemEdit” with clinical-grade iPS cells to produce and commercialize clinical-grade universal donor iPS cells.